research use only

SL-327 MEK inhibitor

Name: SL-327
Brand: Selleck Chemicals
SKU: S1066
Availability: InStock
Rating: 5 (12 reviews)

Cat.No.S1066

SL327 is a selective inhibitor for MEK1/2 with IC50 of 0.18 μM/ 0.22 μM, no activity towards Erk1, MKK3, MKK4, c-JUN, PKC, PKA, or CamKII;capable of transport through the blood-brain barrier.

Chemical Structure

Molecular Weight: 335.35

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: Purity: 100.00%

100.00

Related Targets	Ras ERK p38 MAPK Raf JNK S6 Kinase MAP4K TAK1 Mixed Lineage Kinase ASK MNK MAPKAPK2 KLF TOPK
Related Products	Mirdametinib (PD0325901) U0126-EtOH PD98059 PD184352 (CI-1040) BIX 02189 Pimasertib (AS-703026) Refametinib (RDEA119) TAK-733 AZD8330 BIX 02188 GDC-0623 Myricetin BI-847325 PD318088 APS-2-79 HCl MEK1 Antibody [F9N7] PD184161 Nedometinib MEK1 Antibody [G24C19] GW284543 (UNC10225170) RO4987655 Atebimetinib (IMM-1-104) MEK1/2 Antibody [J11P23] Zapnometinib (PD0184264) Tunlametinib Phospho-MEK1/2 (Ser217/221) Antibody [G6P21] Rap1B Antibody [H22K21] MEK2 Antibody [M18L8] Rap1A/Rap1B Antibody [E5J15] MKK3 Antibody [E15H14]

Chemical Information, Storage & Stability

Molecular Weight	335.35	Formula	C₁₆H₁₂F₃N₃S	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	305350-87-2	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			Smiles	C1=CC=C(C(=C1)C(=C(N)SC2=CC=C(C=C2)N)C#N)C(F)(F)F

Solubility

In vitro
Batch:

DMSO : 67 mg/mL (199.79 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	MEK1 ^[3] 0.18 μM MEK2 ^[3] 0.22 μM AP-1 ^[3] 2.03 μM
In vitro	SL327 is a structural homologue of the specific MKK1/2 inhibitor U0126 with IC50 of 0.18 μM and 0.22 μM for MEK1 and MEK2 respectively. SL327 has no effect on a variety of other kinases, including PKA, PKC, or CamKII. ^[1]
In vivo	SL327 (50 mg/kg) crosses the blood-brain barrierand and blocks fear conditioning by inhibiting MAPK/ERK phosphorylation. ^[2] SL327 (30 mg/kg) significantly impairs spatial learning in mice. ^[3] SL327 (50 mg/kg) blocks cocaine-induced properties. ^[4]
References	[1] https://pubmed.ncbi.nlm.nih.gov/10969080/ [2] https://pubmed.ncbi.nlm.nih.gov/10196568/ [3] http://www.ncbi.nlm.nih.gov/pubmed?term=10541468 [4] https://pubmed.ncbi.nlm.nih.gov/11102476/

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):